SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.15  Revision Date: 10.10.2020  SDS Number: 52866-00018  Date of last issue: 19.05.2020

Revision Date: 10.10.2020  SDS Number: 52866-00018  Date of last issue: 19.05.2020

Date of first issue: 02.02.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name: Ivermectin / Pyrantel Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company: MSD
   Shotton Lane
   NE23 3JU Cramlington NU - Great Britain
   Telephone: 44 1 670 59 30 00
   Telefax: 908-735-1496
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Short-term (acute) aquatic hazard, Category 1: H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1: H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms: 
   
   Signal word: Warning
   Hazard statements: H410 Very toxic to aquatic life with long lasting effects.
   Precautionary statements: Prevention:
   P273 Avoid release to the environment.
Response:
P391 Collect spillage.

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.6 %

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>244-837-1</td>
<td></td>
<td></td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>274-536-0</td>
<td></td>
<td>Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.
            Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
                         Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
                         Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
               Get medical attention if symptoms occur.
               Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of the skin.
        Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
                               Alcohol-resistant foam
                               Carbon dioxide (CO2)
                               Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
                                    Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
                                Nitrogen oxides (NOx)
                                Sulphur oxides
                                Metal oxides
                                Chlorine compounds
5.3 Advice for firefighters

Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.
Advice on safe handling: Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>TWA</td>
<td>25 ppm 79 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin

| Wipe limit | 0.5 mg/100 cm² | Internal |
Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>168 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>D-Glucono-1,5-lactone</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>59 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>11.9 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>14.6 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>5.9 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>5.9 mg/kg bw/day</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kgbw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Fresh water</td>
<td>260 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>26 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>183 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>572 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>57.2 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>50 mg/kg</td>
</tr>
</tbody>
</table>

6 / 19
SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

**Appearance**: powder

**Colour**: brown
Odour: No data available
Odour Threshold: No data available

pH: 4 - 6 (20 °C)
(as aqueous solution)

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available
Flash point: Not applicable

Evaporation rate: Not applicable

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapour pressure: Not applicable
Relative vapour density: Not applicable
Relative density: No data available
Density: No data available

Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Auto-ignition temperature: No data available

Decomposition temperature: No data available

Viscosity
Viscosity, kinematic: Not applicable

Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids): No data available
Particle size: No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Acute oral toxicity: LD50 (Rat): > 24.000 mg/kg
LD50 (Mouse): > 24.000 mg/kg
LD50 (Dog): 2.000 mg/kg

Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Ivermectin / Pyrantel Formulation

Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity:
LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity:
LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Ivermectin:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Ivermectin:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Ivermectin:
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

Germ cell mutagenicity
Not classified based on available information.

Components:
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Ivermectin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
   Result: negative

   Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
   Test system: human diploid fibroblasts
   Result: negative

   Test Type: Mouse Lymphoma
   Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Ivermectin:
Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
Not classified based on available information.

Components:
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Effects on foetal development: Test Type: Embryo-foetal development
   Species: Rat
   Application Route: Oral
   Developmental Toxicity: NOAEL: 3.000 mg/kg body weight
   Result: No effects on fertility and early embryonic development were detected.

   Test Type: Embryo-foetal development
   Species: Rabbit
   Application Route: Oral
   Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
   Result: No effects on fertility and early embryonic development were detected.
Ivermectin / Pyrantel Formulation

Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Oral
- Fertility: NOAEL: 0.6 mg/kg body weight
- Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
- Test Type: Development
- Species: Mouse
- Application Route: Oral
- Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
- Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
- Result: Embryotoxic effects and adverse effects on the offspring were detected. Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT - single exposure
Not classified based on available information.

Components:
Ivermectin:
- Target Organs: Central nervous system
- Assessment: Causes damage to organs.

STOT - repeated exposure
Not classified based on available information.

Components:
Ivermectin:
- Target Organs: Central nervous system
- Assessment: Causes damage to organs through prolonged or repeated exposure.
**Repeated dose toxicity**

**Components:**

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>10 mg/kg</td>
<td>30 mg/kg</td>
<td>Ingestion</td>
<td>3 d</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Dog</td>
<td>600 mg/kg</td>
<td></td>
<td>Oral</td>
<td>19 d</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Dog</td>
<td>600 mg/kg</td>
<td></td>
<td>Oral</td>
<td>30 d</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Dog</td>
<td>600 mg/kg</td>
<td></td>
<td>Oral</td>
<td>90 d</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>0.5 mg/kg</td>
<td>1 mg/kg</td>
<td>Oral</td>
<td>14 Weeks</td>
<td>Central nervous system</td>
<td>Dilatation of the pupil, Tremors, Lack of coordination, anorexia</td>
</tr>
<tr>
<td>Monkey</td>
<td>1,2 mg/kg</td>
<td></td>
<td>Oral</td>
<td>2 Weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>0.4 mg/kg</td>
<td>0.8 mg/kg</td>
<td>Oral</td>
<td>3 Months</td>
<td>spleen, Bone marrow, Kidney</td>
<td></td>
</tr>
</tbody>
</table>

Remarks: No significant adverse effects were reported
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-
methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

SECTION 12: Ecological information

12.1 Toxicty

Components:
4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-
methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment
Acute aquatic toxicity: Toxic effects cannot be excluded
Chronic aquatic toxicity: Toxic effects cannot be excluded

Ivermectin:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l
Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0,000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 10.000
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.15  Revision Date: 10.10.2020  SDS Number: 52866-00018  Date of last issue: 19.05.2020

M-Factor (Chronic aquatic toxicity) : 10.000

12.2 Persistence and degradability

**Components:**

Ivermectin:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

12.3 Bioaccumulative potential

**Components:**

Ivermectin:
Bioaccumulation : Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water : log Pow: 3.22

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product** : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging** : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

<table>
<thead>
<tr>
<th>Code</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>UN 3077</td>
</tr>
<tr>
<td>ADR</td>
<td>UN 3077</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3077</td>
</tr>
<tr>
<td></td>
<td>ADN</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>UN</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IMDG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M7</td>
<td>M7</td>
<td>M7</td>
<td>M7</td>
<td>M7</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Tunnel restriction code</td>
<td>(-)</td>
<td>(-)</td>
<td>(-)</td>
<td>(-)</td>
<td>(-)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>EmS Code</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Un</td>
<td>F-A, S-F</td>
<td></td>
</tr>
</tbody>
</table>
Ivermectin / Pyrantel Formulation

SECTION 14: Transport information

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollu-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.15 Revision Date: 10.10.2020 SDS Number: 52866-00018 Date of last issue: 19.05.2020
Date of first issue: 02.02.2015

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals:

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300 : Fatal if swallowed.
H311 : Toxic in contact with skin.
H370 : Causes damage to organs if swallowed.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure
FOR-2011-12-06-1358 : Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / : Long term exposure limit
TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentra-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.15
Revision Date: 10.10.2020
SDS Number: 52866-00018
Date of last issue: 19.05.2020
Date of first issue: 02.02.2015

Further information
Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
Aquatic Acute 1: H400
Aquatic Chronic 1: H410

Classification procedure:
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN